Activity of Cefiderocol and Comparators against Isolates from Cancer Patients

被引：49
作者：
Rolston, Kenneth V. I. [1 ]
Gerges, Baghat [1 ]
Shelburne, Samuel [1 ]
Aitken, Samuel L. [2 ]
Raad, Issam [1 ]
Prince, Randall A. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Infect Dis Infect Control & Employee Hlth, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Div Pharm, Houston, TX 77030 USA
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2020年 / 64卷 / 05期
关键词：
Gram-negative isolates; Pseudomonas aeruginosa; Stenotrophomonas maltophilia; cefiderocol; VITRO ANTIMICROBIAL ACTIVITY; SIDEROPHORE CEPHALOSPORIN; S-649266;
D O I：
10.1128/AAC.01955-19
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Cefiderocol inhibited 97.5% of 478 Gram-negative isolates from cancer patients at <= 4 mg/liter. It had potent activity against extended-spectrum beta-lactamase-positive Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae (CRE), and nonfermenting Gram-negative bacilli, including Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Acinetobacter species isolates. Amikacin, ceftazidime-avibactam, and meropenem had appreciable activity against non-CRE Enterobacteriaceae. No comparators were active against multidrug-resistant P. aeruginosa isolates. Only trimethoprim-sulfamethoxazole had appreciable activity against S. maltophilia isolates. Overall, cefiderocol was associated with the lowest level of resistance.
引用
收藏
页数：7
相关论文
共 10 条
  • [1] Castanheir M, 2019, ANTIMICROB AGENTS CH, V63, DOI [10.1128/AAC.00160-19, 10.1128/aac.00160-19]
  • [2] Clinical and Laboratory Standards Institute, 2019, 100 CLSI
  • [3] Freifeld AG, 2011, CLIN INFECT DIS, V52, pE56, DOI 10.1093/cid/cir073
  • [4] In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria
    Ito, Akinobu
    Kohira, Naoki
    Bouchillon, Samuel K.
    West, Joshua
    Rittenhouse, Stephen
    Sader, Helio S.
    Rhomberg, Paul R.
    Jones, Ronald N.
    Yoshizawa, Hidenori
    Nakamura, Rio
    Tsuji, Masakatsu
    Yamano, Yoshinori
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016, 71 (03) : 670 - 677
  • [5] Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases
    Ito-Horiyama, Tsukasa
    Ishii, Yoshikazu
    Ito, Akinobu
    Sato, Takafumi
    Nakamura, Rio
    Fukuhara, Norio
    Tsuji, Masakatsu
    Yamano, Yoshinori
    Yamaguchi, Keizo
    Tateda, Kazuhiro
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (07) : 4384 - 4386
  • [6] Kenneth VI, 2018, ECCMID 2018
  • [7] In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains
    Kohira, Naoki
    West, Joshua
    Ito, Akinobu
    Ito-Horiyama, Tsukasa
    Nakamura, Rio
    Sato, Takafumi
    Rittenhouse, Stephen
    Tsuji, Masakatsu
    Yamano, Yoshinori
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (02) : 729 - 734
  • [8] Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance
    Montassier, E.
    Batard, E.
    Gastinne, T.
    Potel, G.
    de La Cochetiere, M. F.
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2013, 32 (07) : 841 - 850
  • [9] "Stormy waters ahead": global emergence of carbapenemases
    Patel, Gopi
    Bonomo, Robert A.
    [J]. FRONTIERS IN MICROBIOLOGY, 2013, 4
  • [10] The emerging problem of bacterial resistance in cancer patients; proceedings of a workshop held by MASCC "Neutropenia, Infection and Myelosuppression" Study Group during the MASCC annual meeting held in Berlin on 27-29 June 2013
    Rapoport, Bernardo
    Klastersky, Jean
    Raftopoulos, Harry
    Freifeld, Allison
    Aoun, Mickael
    Zinner, Stephen H.
    Rolston, Kenneth V. I.
    [J]. SUPPORTIVE CARE IN CANCER, 2016, 24 (07) : 2819 - 2826
1